Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Checkpoint Therapeutics

Checkpoint Therapeutics
2014 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
CKPT STOCK SYMBOL
$1.27 SHARE PRICE (As of Thursday Closing)
Description

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 3 Columbus Circle
  • 15th Floor
  • New York, NY 10019
  • United States

+1 (781) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Checkpoint Therapeutics’s full profile, request a free trial.

Checkpoint Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.12 - $5.20 $48.5M $1.18 -$0.86 150K 38.2M

Checkpoint Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 81,404 32,365 75,553
Revenue 4,714 3,506 1,725 2,570
EBITDA (27,660) (36,515) (22,775) (22,164)
Net Income (27,507) (36,367) (22,677) (22,461)
Total Assets 14,080 24,899 21,413 35,978
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Checkpoint Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Checkpoint Therapeutics‘s full profile, request access.

Request full access to PitchBook

Checkpoint Therapeutics Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Metacrine Venture Capital-Backed San Diego, CA 00 00000 000000000 00000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
00000000 000000000 Corporation West Conshohocken, PA 00 000.00 000000 - 000 000.00
00000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 0 000.00
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 0000000000 0 00000
To view this company’s complete list of competitors, request access »

Checkpoint Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
James Oliviero III Chief Executive Officer & Board Member
David Horin Interim Chief Financial Officer

Checkpoint Therapeutics Board Members (1)

Name Representing Role Since Contact
Info
00000 00000000 000 Checkpoint Therapeutics Chief Executive Officer & Board Member 000 0000